<DOC>
	<DOCNO>NCT01322490</DOCNO>
	<brief_summary>The purpose study determine whether PROSTVAC alone combination GM-CSF effective prolong overall survival men symptom metastatic , castrate-resistant prostate cancer .</brief_summary>
	<brief_title>A Randomized , Double-blind , Phase 3 Efficacy Trial PROSTVAC-V/F +/- GM-CSF Men With Asymptomatic Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>BNIT-PRV-301 randomize , placebo-controlled , multi-center , global Phase 3 efficacy trial PROSTVAC men asymptomatic minimally symptomatic , metastatic , castrate-resistant prostate cancer . It 3-arm study evaluate overall survival two separate comparison , PROSTVAC plus adjuvant dose GM-CSF versus control , PROSTVAC without GM-CSF versus control . Patients randomize equal probability one three double-blind arm . The intended intervention randomize patient : 1 . ( Arm V+G ) PROSTVAC-V/F plus adjuvant dose GM-CSF 2 . ( Arm V ) PROSTVAC-V/F plus GM-CSF placebo 3 . ( Arm P ) Double placebo</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men , ≥18years age document asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer . Documented progressive disease post surgical castration androgen suppression therapy , complete androgen blockade therapy withdrawal . Documented either criterion ( Radiological progression ) , OR criterion b ( PSA progression ) . 1 . Radiological progression define new/enlarging bone metastasis new/enlarging lymph node disease , consistent prostate cancer . OR 2 . PSA progression define sequence rise value separate &gt; 1 week ( 2 separate increase value ) threshold minimum 2.0 ng/ml . ( PCWG2 PSA eligibility criterion ) . Chemotherapy naïve Vacciniaexperienced ( previous smallpox vaccination ) . Currently use GnRH agonist antagonist ( unless surgically castrate ) . Cancerrelated pain require schedule opioid narcotic control ( need , ≤ 2x per week allow ) . Metastasis organ system lymph node and/or bone . Estimated PSA double time &lt; 1 month establish within 6 month anticipate first dose vaccine placebo . Concurrent prior Provenge ( sipuleucelT ) immunotherapy prostate cancer . Receipt investigational agent within 30 day ( 60 day antibodybased therapy ) first plan dose PROSTVACV/F . History prior malignancy prostate cancer within past 3 year , exclude successfully resect basal squamous cell carcinoma skin . Congestive heart failure ( NYHA Class II , III , IV ) , unstable angina , ventricular hemodynamically significant atrial arrhythmia , cardiovascular disease stroke myocardial infarction ( current within past 6 month ) Confirmed positive HIV , hepatitis B , /or hepatitis C. Immunodeficiency splenectomy . History active autoimmune disease , person vitiligo exclude . Diabetics exclude condition well control . History atopic dermatitis active skin condition ( acute , chronic , exfoliative ) disrupt epidermis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PROSTVAC</keyword>
	<keyword>metastatic</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>castrate-resistant</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Phase 3</keyword>
</DOC>